Apyx Medical (NASDAQ:APYX) Upgraded at Roth Capital

Roth Capital upgraded shares of Apyx Medical (NASDAQ:APYX) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Several other analysts also recently issued reports on APYX. Citizens Jmp raised shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research note on Wednesday, November 12th. Wall Street Zen upgraded Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Apyx Medical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.00.

Apyx Medical Trading Down 1.9%

Apyx Medical stock opened at $3.65 on Monday. The firm has a market cap of $139.58 million, a price-to-earnings ratio of -10.14 and a beta of 1.49. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $4.44. The firm’s 50 day moving average price is $3.60 and its two-hundred day moving average price is $2.62. The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The firm had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $12.00 million. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%. On average, research analysts predict that Apyx Medical will post -0.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Apyx Medical

A number of hedge funds have recently added to or reduced their stakes in the company. Silverberg Bernstein Capital Management LLC grew its position in shares of Apyx Medical by 38.7% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 896,736 shares of the company’s stock valued at $2,018,000 after purchasing an additional 250,167 shares during the last quarter. Kingsview Wealth Management LLC boosted its stake in Apyx Medical by 9.4% during the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock valued at $431,000 after purchasing an additional 16,502 shares during the period. Nantahala Capital Management LLC boosted its stake in Apyx Medical by 2.8% during the 1st quarter. Nantahala Capital Management LLC now owns 3,258,048 shares of the company’s stock valued at $4,464,000 after purchasing an additional 88,248 shares during the period. Vanguard Group Inc. grew its holdings in Apyx Medical by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after buying an additional 53,175 shares during the last quarter. Finally, Franklin Resources Inc. bought a new position in Apyx Medical in the 3rd quarter worth approximately $59,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.